Getting Past HSC Security: Cyclosporine H Gives Lentiviruses an Entry Pass

Daniel E Bauer; Sung-Yun Pai

doi:10.1016/j.stem.2018.11.008

Getting Past HSC Security: Cyclosporine H Gives Lentiviruses an Entry Pass

Cell Stem Cell. 2018 Dec 6;23(6):775-776. doi: 10.1016/j.stem.2018.11.008.

Authors

Daniel E Bauer¹, Sung-Yun Pai²

Affiliations

¹ Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA; Broad Institute, Massachusetts Institute of Technology, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA.
² Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: [email protected].

PMID: 30526877
DOI: 10.1016/j.stem.2018.11.008

Abstract

In this issue of Cell Stem Cell, Petrillo et al. (2018) improve lentiviral transduction of hematopoietic stem cells (HSCs) by using cyclosporine H to relieve viral entry restriction by interferon-induced transmembrane protein 3 (IFITM3). This finding promises to enhance the efficiency of ex vivo therapeutic gene transfer and gene editing of HSCs.

Publication types

Comment

MeSH terms

Cyclosporine
Gene Editing*
Hematopoietic Stem Cells
Humans
Immunity, Innate
Lentivirus / genetics*
Membrane Proteins
RNA-Binding Proteins

Substances

IFITM3 protein, human
Membrane Proteins
RNA-Binding Proteins
Cyclosporine
cyclosporin H